QuidelOrtho (NASDAQ:QDEL) Issues FY 2025 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 2.000-2.150 for the period, compared to the consensus EPS estimate of 2.260. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion.

QuidelOrtho Trading Down 4.3%

Shares of NASDAQ:QDEL traded down $0.91 during trading on Friday, reaching $20.35. 3,301,351 shares of the company traded hands, compared to its average volume of 1,331,805. The company has a current ratio of 1.12, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. QuidelOrtho has a 52-week low of $20.10 and a 52-week high of $49.45. The business’s fifty day moving average is $28.31 and its 200-day moving average is $28.41. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -3.11 and a beta of 0.35.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.29. The business had revenue of $699.90 million for the quarter, compared to analysts’ expectations of $667.45 million. QuidelOrtho had a negative net margin of 16.10% and a positive return on equity of 5.29%. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.85 earnings per share. QuidelOrtho has set its FY 2025 guidance at 2.000-2.150 EPS. As a group, analysts forecast that QuidelOrtho will post 2.3 EPS for the current year.

Analyst Ratings Changes

QDEL has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Wednesday, October 8th. Wall Street Zen downgraded QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Saturday, July 26th. JPMorgan Chase & Co. reduced their price target on shares of QuidelOrtho from $26.00 to $22.00 and set an “underweight” rating for the company in a research report on Friday. Citigroup reiterated a “neutral” rating and issued a $33.00 price objective (down previously from $40.00) on shares of QuidelOrtho in a research note on Tuesday, October 7th. Finally, Zacks Research lowered shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $38.20.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in QDEL. California State Teachers Retirement System raised its stake in shares of QuidelOrtho by 1.2% during the second quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock valued at $1,792,000 after acquiring an additional 725 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in QuidelOrtho by 250.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock valued at $93,000 after purchasing an additional 2,309 shares in the last quarter. Orion Porfolio Solutions LLC raised its position in QuidelOrtho by 11.9% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 22,551 shares of the company’s stock valued at $650,000 after purchasing an additional 2,392 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of QuidelOrtho by 298.1% in the 2nd quarter. Osaic Holdings Inc. now owns 3,300 shares of the company’s stock worth $95,000 after buying an additional 2,471 shares during the period. Finally, State of Wyoming grew its position in shares of QuidelOrtho by 230.5% during the 2nd quarter. State of Wyoming now owns 4,524 shares of the company’s stock worth $130,000 after buying an additional 3,155 shares in the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.